Global Ethinylestradiol Market Size, Share and Trends Analysis Report, By Application (Estrogen and Female Contraceptive), Forecast (2022-2028)

The global ethinylestradiol market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Ethinylestradiol is a man-made form of the naturally occurring female hormone called estrogen. It is prescribed to treat menstrual cycle problems, and also to help ease menopausal symptoms. It is usually prescribed alongside another female hormone called a progestogen. The global ethinylestradiol market is growing due to the rising prevalence of menstrual problems globally. According to an article published by the US National Library of Medicine in January 2018, a cross-sectional study was conducted in the health colleges of Immam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia, where 91% of the students were suffering from some kind of menstrual problem. The market is also growing due to the rise in psychological stress and anxiety among young females globally which is directly impacting female menstrual problems around the globe. According to American Psychological Association, women are likely to have 28% more psychological stress than men and almost half of all women around 49% surveyed said their stress has increased over the past five years, compared to four in ten, i.e., 39% men. Therefore, the increasing menstrual problem and rise in psychological stress and anxiety among young females are anticipated to propel the growth of the global ethinylestradiol market during the forecast period.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new drug launches, to stay competitive in the market. For instance-

• In August 2021, Amneal Pharmaceuticals LLC launched Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules in 1 mg/20 mcg variant after its Abbreviated New Drug Application (ANDA) from the USFDA.
• In February 2021, Slayback Pharma LLC launched Merzee composition of norethindrone acetate and Ethinyl estradiol capsules and ferrous fumarate capsules in 1 mg/20 mcg variant and fulfilled customer orders for the product.
• In January 2021, Teva Pharmaceutical Industries Ltd. launched NuvaRing with the composition of etonogestrel and Ethinyl estradiol vaginal ring, in 0.120 mg/0.015 mg variant, in the US market to prevent women pregnancy.
• In December 2020, Agile Therapeutics announced their commercial launch of Twirla which is a composition of levonorgestrel and Ethinyl estradiol transdermal system in the US market to treat combined hormonal contraceptives to prevent pregnancy.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Aurobindo Pharma, Novartis AG, Bayer AG, Pfizer Inc., Organon group of companies, and Aspen Holdings, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Ethinylestradiol Market Report by Segment

By Application

• Estrogen
• Female Contraceptive

Global Ethinylestradiol Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa